Independent
Tenure on this board
3.8 yrs
Also a director at
Enliven Therapeutics Inc (ELVN)
3 nominees · 4 ballot items.
Elect three Class I directors; advisory vote to approve named executive officer compensation; approve amendment to 2023 Stock Incentive Plan to add 2,000,000 shares; ratify PwC as independent auditors.
Elect three Class I director nominees (Rahul Ballal, Ph.D.; Brian Goff; Cynthia Smith) to serve three-year terms ending in 2029.
Non-binding advisory vote to approve compensation of named executive officers as disclosed in proxy materials.
The proposal asks shareholders to approve, on a non-binding advisory basis, the company's named executive officer compensation as disclosed in the proxy, intended to affirm alignment of pay with performance and retention objectives. Management seeks endorsement to validate its compensation philosophy, which emphasizes a mix of base salary, performance-based cash incentives, and long-term equity awards (options, RSUs, PSUs) tied to clinical, regulatory and commercial milestones. The board recommends a vote FOR, citing strong prior say-on-pay support (~94% in 2025) and policies discouraging excessive risk-taking (clawback, no repricing, anti-hedging). Context: recent corporate milestones in 2025 include FDA approvals and commercial launch of AQVESME™, progress in RISE UP SCD trial and pipeline advancements, which informed compensation determinations. A sophisticated evaluator should weigh whether the mix of PSUs and time-based awards appropriately aligns long-term incentives with shareholder value, consider the sizable at-risk component of CEO pay (89% at-risk in 2025), and note compensation committee engagement with independent consultant Aon. Also consider engagement results, potential dilution from equity grants, and governance safeguards (stock ownership guidelines, clawback policy).
Approve amendment to increase shares available under the 2023 Stock Incentive Plan by 2,000,000 shares (and incentive stock option limit accordingly).
Management seeks shareholder approval to increase the 2023 Stock Incentive Plan by 2,000,000 shares to replenish the equity pool used for employee, consultant and non-employee director awards. This request follows a recent 2,500,000-share increase in 2025 and reflects management’s assessment that the remaining reserve has been consumed by historic grant levels. The board frames the increase as necessary to attract and retain talent in a competitive biotech market, emphasizing pay-for-performance features (significant use of PSUs tied to clinical/regulatory/commercial milestones, no evergreen provision) and governance protections (no repricing without shareholder approval, limits on non-employee director compensation, clawback policy). Analytical considerations: approving increases dilution (overhang ~19.6% as of March 31, 2026; would rise to ~23.0% with the new shares), but the requested amount equates to ~3.4% of outstanding shares and sustains anticipated grant rates for roughly one year; the board modeled burn rate (three-year average gross burn rate ~3.9%). Investors should weigh potential dilution against the importance of equity in competitive hiring and retention, the company's execution risks and recent milestones (FDA approvals and commercial launch), and whether plan governance features adequately protect shareholders. Review of substitute award provisions, share recycling rules, and the lack of an evergreen provision are relevant to long-term dilution control.
Ratify the audit committee’s appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT LLCActivist | 9.56% | 5,684,000 | $192M |
| 2 | STATE STREET CORP | 5.66% | 3,364,879 | $114M |
| 3 | ARMISTICE CAPITAL, LLC | 4.57% | 2,716,000 | $92M |
| 4 | Erste Asset Management GmbH | 4.55% | 2,704,900 | $80M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 4.43% | 2,632,316 | $89M |
| 6 | Lynx1 Capital Management LP | 4.39% | 2,611,568 | $88M |
| 7 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.39% | 2,611,035 | $88M |
| 8 | BlackRock, Inc. | 4.05% | 2,410,755 | $82M |
| 9 | D. E. Shaw Co., Inc.Activist | 3.36% | 1,998,058 | $68M |
| 10 | BlackRock, Inc. | 3.14% | 1,867,825 | $63M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.